Myles Minter
Stock Analyst at William Blair
(4.89)
# 298
Out of 5,078 analysts
615
Total ratings
49.9%
Success rate
25.1%
Average return
Main Sectors:
Stocks Rated by Myles Minter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Initiated Coverage: Buy | n/a | $18.26 | - | 1 | Oct 21, 2026 | |
| SLN Silence Therapeutics | Downgraded: Hold | n/a | $19.67 | - | 28 | Oct 19, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | n/a | $68.56 | - | 12 | Oct 6, 2026 | |
| ANRO Alto Neuroscience | Reiterated: Buy | n/a | $21.97 | - | 15 | Oct 2, 2026 | |
| CTNM Contineum Therapeutics | Reiterated: Buy | n/a | $8.31 | - | 12 | Sep 30, 2026 | |
| CAMP Camp4 Therapeutics | Reiterated: Buy | n/a | $3.30 | - | 13 | Sep 29, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | n/a | $9.84 | - | 23 | Sep 24, 2026 | |
| RAPP Rapport Therapeutics | Reiterated: Buy | n/a | $25.93 | - | 4 | Sep 23, 2026 | |
| VTGN Vistagen Therapeutics | Reiterated: Hold | n/a | $0.1797 | - | 14 | Sep 23, 2026 | |
| IONS Ionis Pharmaceuticals | Reiterated: Buy | n/a | $42.93 | - | 55 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $523.93 | - | 35 | Sep 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $76.78 | - | 22 | Sep 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $35.34 | - | 16 | Sep 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $7.41 | - | 15 | Sep 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.88 | - | 14 | Sep 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $200.10 | - | 30 | Aug 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.3794 | - | 16 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.16 | - | 11 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $145.04 | - | 64 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.83 | - | 12 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $18.41 | - | 14 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.98 | - | 12 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.21 | - | 18 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.35 | - | 20 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.41 | - | 13 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $142.70 | - | 32 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $224.03 | - | 17 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $250.69 | - | 31 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $873.71 | - | 19 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $15.39 | - | 1 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.52 | n/a | 3 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $3.44 | n/a | 3 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $252.96 | n/a | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.30 | n/a | 15 | Dec 29, 2022 |
Vor Biopharma
Oct 21, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $18.26
Upside: -
Silence Therapeutics
Oct 19, 2026
Downgraded: Hold
Price Target: n/a
Current: $19.67
Upside: -
BridgeBio Pharma
Oct 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $68.56
Upside: -
Alto Neuroscience
Oct 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $21.97
Upside: -
Contineum Therapeutics
Sep 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $8.31
Upside: -
Camp4 Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.30
Upside: -
Arcturus Therapeutics Holdings
Sep 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $9.84
Upside: -
Rapport Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $25.93
Upside: -
Vistagen Therapeutics
Sep 23, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.1797
Upside: -
Ionis Pharmaceuticals
Sep 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $42.93
Upside: -
Sep 22, 2026
Reiterated: Buy
Price Target: n/a
Current: $523.93
Upside: -
Sep 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $76.78
Upside: -
Sep 18, 2026
Reiterated: Buy
Price Target: n/a
Current: $35.34
Upside: -
Sep 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $7.41
Upside: -
Sep 9, 2026
Rated: Hold
Price Target: n/a
Current: $13.88
Upside: -
Aug 19, 2026
Upgraded: Buy
Price Target: n/a
Current: $200.10
Upside: -
Aug 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.3794
Upside: -
Aug 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.16
Upside: -
Aug 10, 2026
Reiterated: Buy
Price Target: n/a
Current: $145.04
Upside: -
Aug 7, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.83
Upside: -
Aug 7, 2026
Reiterated: Buy
Price Target: n/a
Current: $18.41
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.98
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.21
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.35
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.41
Upside: -
Jul 31, 2026
Reiterated: Buy
Price Target: n/a
Current: $142.70
Upside: -
Jul 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $224.03
Upside: -
Jul 29, 2026
Reiterated: Buy
Price Target: n/a
Current: $250.69
Upside: -
Jun 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $873.71
Upside: -
Mar 31, 2026
Reiterated: Buy
Price Target: n/a
Current: $15.39
Upside: -
Dec 22, 2023
Rated: Hold
Price Target: n/a
Current: $2.52
Upside: n/a
Sep 28, 2023
Reiterated: Buy
Price Target: n/a
Current: $3.44
Upside: n/a
Mar 3, 2023
Downgraded: Hold
Price Target: n/a
Current: $252.96
Upside: n/a
Dec 29, 2022
Rated: Hold
Price Target: n/a
Current: $2.30
Upside: n/a